Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients
Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer´s disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA levels may...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/10/4/571 |
| _version_ | 1797571098177437696 |
|---|---|
| author | Marta González-Sánchez Javier Jiménez Arantzazu Narváez Desiree Antequera Sara Llamas-Velasco Alejandro Herrero-San Martín Jose Antonio Molina Arjona Adolfo López de Munain Alberto Lleó Bisa M.-Pilar Marco Montserrat Rodríguez-Núñez David Andrés Pérez-Martínez Alberto Villarejo-Galende Fernando Bartolome Elena Domínguez Eva Carro |
| author_facet | Marta González-Sánchez Javier Jiménez Arantzazu Narváez Desiree Antequera Sara Llamas-Velasco Alejandro Herrero-San Martín Jose Antonio Molina Arjona Adolfo López de Munain Alberto Lleó Bisa M.-Pilar Marco Montserrat Rodríguez-Núñez David Andrés Pérez-Martínez Alberto Villarejo-Galende Fernando Bartolome Elena Domínguez Eva Carro |
| author_sort | Marta González-Sánchez |
| collection | DOAJ |
| description | Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer´s disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA levels may suggest an inflammatory response. Very recently, significant increases in KYNA levels were reported in cerebrospinal fluid (CSF) from AD patients compared with normal controls. In this study, we assessed the accuracy of KYNA in CSF for the classification of patients with AD, cognitively healthy controls, and patients with a variety of other neurodegenerative diseases, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and progressive supranuclear palsy (PSP). Averaged KYNA concentration in CSF was higher in patients with AD when compared with healthy subjects and with all the other differentially diagnosed groups. There were no significant differences in KYNA levels in CSF between any other neurodegenerative groups and controls. These results suggest a specific increase in KYNA concentration in CSF from AD patients not seen in other neurodegenerative diseases. |
| first_indexed | 2024-03-10T20:35:41Z |
| format | Article |
| id | doaj.art-405350ab088d471c83af58a3ed0faadf |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T20:35:41Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-405350ab088d471c83af58a3ed0faadf2023-11-19T21:02:50ZengMDPI AGBiomolecules2218-273X2020-04-0110457110.3390/biom10040571Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease PatientsMarta González-Sánchez0Javier Jiménez1Arantzazu Narváez2Desiree Antequera3Sara Llamas-Velasco4Alejandro Herrero-San Martín5Jose Antonio Molina Arjona6Adolfo López de Munain7Alberto Lleó Bisa8M.-Pilar Marco9Montserrat Rodríguez-Núñez10David Andrés Pérez-Martínez11Alberto Villarejo-Galende12Fernando Bartolome13Elena Domínguez14Eva Carro15Group of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, SpainDepartment of Analytical Chemistry, Physical Chemistry and Chemical Engineering, University of Alcalá, 28871 Alcalá de Henares, SpainDepartment of Analytical Chemistry, Physical Chemistry and Chemical Engineering, University of Alcalá, 28871 Alcalá de Henares, SpainGroup of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, SpainGroup of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, SpainGroup of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, SpainGroup of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, SpainBiomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), 28031 Madrid, SpainBiomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), 28031 Madrid, SpainNanobiotechnology for Diagnostics (Nb4D) Group, Institute for Advanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC), 08034 Barcelona, SpainNanobiotechnology for Diagnostics (Nb4D) Group, Institute for Advanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC), 08034 Barcelona, SpainGroup of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, SpainGroup of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, SpainGroup of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, SpainDepartment of Analytical Chemistry, Physical Chemistry and Chemical Engineering, University of Alcalá, 28871 Alcalá de Henares, SpainGroup of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, SpainKynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer´s disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA levels may suggest an inflammatory response. Very recently, significant increases in KYNA levels were reported in cerebrospinal fluid (CSF) from AD patients compared with normal controls. In this study, we assessed the accuracy of KYNA in CSF for the classification of patients with AD, cognitively healthy controls, and patients with a variety of other neurodegenerative diseases, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and progressive supranuclear palsy (PSP). Averaged KYNA concentration in CSF was higher in patients with AD when compared with healthy subjects and with all the other differentially diagnosed groups. There were no significant differences in KYNA levels in CSF between any other neurodegenerative groups and controls. These results suggest a specific increase in KYNA concentration in CSF from AD patients not seen in other neurodegenerative diseases.https://www.mdpi.com/2218-273X/10/4/571Alzheimer´s diseasekynurenine pathwaycerebrospinal fluidbiomarkersamyloid-βtau protein |
| spellingShingle | Marta González-Sánchez Javier Jiménez Arantzazu Narváez Desiree Antequera Sara Llamas-Velasco Alejandro Herrero-San Martín Jose Antonio Molina Arjona Adolfo López de Munain Alberto Lleó Bisa M.-Pilar Marco Montserrat Rodríguez-Núñez David Andrés Pérez-Martínez Alberto Villarejo-Galende Fernando Bartolome Elena Domínguez Eva Carro Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients Biomolecules Alzheimer´s disease kynurenine pathway cerebrospinal fluid biomarkers amyloid-β tau protein |
| title | Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients |
| title_full | Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients |
| title_fullStr | Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients |
| title_full_unstemmed | Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients |
| title_short | Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients |
| title_sort | kynurenic acid levels are increased in the csf of alzheimer s disease patients |
| topic | Alzheimer´s disease kynurenine pathway cerebrospinal fluid biomarkers amyloid-β tau protein |
| url | https://www.mdpi.com/2218-273X/10/4/571 |
| work_keys_str_mv | AT martagonzalezsanchez kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT javierjimenez kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT arantzazunarvaez kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT desireeantequera kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT sarallamasvelasco kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT alejandroherrerosanmartin kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT joseantoniomolinaarjona kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT adolfolopezdemunain kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT albertolleobisa kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT mpilarmarco kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT montserratrodrigueznunez kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT davidandresperezmartinez kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT albertovillarejogalende kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT fernandobartolome kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT elenadominguez kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients AT evacarro kynurenicacidlevelsareincreasedinthecsfofalzheimersdiseasepatients |